The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the chemotherapy ...
1Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Major Finding: Pharmacologic inhibition of EZH2 sensitizes preclinical models of B cell lymphoma to T-cell immunotherapy. Concept: EZH2 inhibition enhances T-cell recruitment, T-cell–B-cell ...
Cancer Res (2024) 84 (24): 4298.
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...
Major Finding: Aging impedes lung tumorigenesis by limiting the stemness of the alveolar type 2 cell of origin. Concept: The effect of age on tumorigenesis is mediated by a disruption of iron ...
Innovent Biologics’ ROS1 tyrosine kinase inhibitor (TKI) taletrectinib adipate (Dovbleron) was approved by the National Medical Products Administration, the Chinese equivalent of the FDA, for patients ...
Major Finding: Gliocidin targets glioblastoma cells by disrupting guanine biosynthesis and driving nucleotide imbalance. Concept: NMNAT1 converts gliocidin to GAD which outcompetes NAD + for IMPDH2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback